Saturday 17 October 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

121.84 0.33 +0.27%

Follow HALO

Alert me

Market cap: $13.8B
P/E: 34.6×
Fwd P/E: 10.6×
Dividend yield: —
F-score: 5/9
Altman Z: 3.46
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 48.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	2	1	1	2	2	2	3	2	2	2	2

Insider Ownership 4.27%

Capital & Financial Ratios $m

Market Cap 13,790.00

Revenue 1,663.74

Net Income 413.60

Free Cash Flow 806.22

Net Debt 1,915.65

Current Ratio 2.71

Debt/Equity 14.95

P/E ratio 34.61

Fwd P/E 10.60

P/S ratio 8.59

P/B ratio 99.54

Past 5Y EPS Growth 22.98%

This Y EPS Growth 107.59%

Next Y EPS Growth 20.81%

Next Y revenue growth 33.90%

Next 5Y EPS Growth 42.80%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 76.37%

10-year low 10-year high

P/S against its own 10 years 44.64%

10-year low 10-year high

P/B against its own 10 years 94.69%

10-year low 10-year high

EV/Sales against its own 10 years 49.80%

10-year low 10-year high

EV/FCF against its own 10 years 61.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	336	596	143	231
Receivables	234	308	441	456
Inventory	128	142	176	137
Other	—	—	—	—
	746	1,085	825	933

	2023	2024	2025	Q'26
Payables	12	10	21	24
ST’ Debt	—	—	—	209
Other	—	—	—	—
	112	139	177	344

Compound Annual Growth %

	10y	5y	3y
Sales	26.32%	39.16%	28.38%
Cash Flow	0.00%	63.68%	39.48%
Earnings	0.00%	19.68%	16.17%
Book Value	1.28%	(20.22%)	(34.00%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	377	481	—	—	—
’25	265	326	354	452	1,397
’24	196	231	290	298	1,015
’23	162	221	216	230	829
’22	117	152	209	181	660
’21	89	136	116	102	443
’20	25	55	65	122	268

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	180	241	—	—	—
’25	154	100	179	219	652
’24	129	56	115	178	479
’23	87	67	132	102	389
’22	48	40	70	82	240
’21	58	37	122	83	299
’20	(5)	3	6	51	55

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	176	237	—	—	—
’25	153	98	624	(231)	645
’24	126	53	425	(136)	468
’23	76	68	325	(96)	373
’22	47	55	69	90	261
’21	58	36	121	82	298
’20	(4)	3	6	49	54

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.22	1.90	—	—	—
’25	0.93	1.33	1.43	(1.20)	2.56
’24	0.60	0.72	1.05	1.06	3.43
’23	0.29	0.56	0.61	0.65	2.10
’22	0.43	0.16	0.44	0.42	1.44
’21	0.19	0.62	1.48	0.46	2.74
’20	(0.04)	0.19	0.25	0.50	0.91

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	6.96	9.68	13.24	13.84	12.71	31.79	31.36	29.85	33.15	47.50	Analyst estimates 2026–2028 Powerpack
	High	17.51	21.13	21.48	19.73	44.53	56.40	59.46	57.00	65.53	79.50
People
People	Employees	259	255	281	132	136	145	393	373	350	423
	Revenue/emp, $m	0.57	1.24	0.54	1.48	1.97	3.06	1.68	2.22	2.90	3.30
Income, $m
Income, $m	Revenue	147	317	152	196	268	443	660	829	1,015	1,397
	Gross margin, %	77.36	90.16	93.33	76.76	83.79	81.64	78.90	76.80	84.30	83.62
	EBT	(102)	62	(80)	(72)	129	249	249	348	557	467
	EBT margin, %	(69.44)	19.46	(52.54)	(36.86)	48.32	56.06	37.71	42.01	54.87	33.43
	Net income	(103)	63	(80)	(72)	129	403	202	282	444	317
	Depreciation	16	4	1	4	18	9	59	86	78	92
Per share, $
Per share, $	Revenue	1.15	2.32	1.06	1.36	1.96	3.15	4.82	6.29	8.01	11.65
	Earnings	(0.81)	0.46	(0.56)	(0.50)	0.95	2.86	1.48	2.13	3.50	2.64
	Cash flow	(0.39)	0.98	(0.34)	(0.59)	0.41	2.13	1.75	2.95	3.78	5.44
	Capex	(0.02)	(0.01)	(0.03)	(0.03)	(0.01)	(0.01)	0.15	(0.12)	(0.08)	(0.06)
	Free cash flow	(0.42)	0.97	(0.38)	(0.62)	0.40	2.12	1.91	2.83	3.69	5.38
	Book value	(0.25)	1.53	1.73	0.64	1.11	1.40	1.24	0.64	2.87	0.41
	Shares, m	128	136	144	144	136	141	137	132	127	120
Valuation, ×
Valuation, ×	P/E	0.00	50.50	0.00	0.00	44.49	14.11	37.25	17.47	13.66	25.79
	P/S	8.71	8.70	13.83	13.06	21.74	12.76	11.43	5.95	5.97	5.77
	P/B	0.00	13.23	8.44	27.89	38.51	28.71	44.43	58.86	16.67	165.22
	EV/Sales	8.79	7.86	12.33	12.96	23.32	13.06	13.16	7.39	6.90	7.72
	EV/FCF	(24.10)	18.75	(34.58)	(28.39)	115.50	19.43	33.25	16.42	14.96	16.72
Cash, $m
Cash, $m	Operating cash flow	(50)	134	(49)	(85)	55	299	240	389	479	652
	Capex	(3)	(1)	(5)	(4)	(1)	(1)	21	(15)	(11)	(7)
	Free cash flow	(54)	133	(54)	(89)	54	298	261	373	468	645
Balance, $m
Balance, $m	Working capital	202	379	278	458	133	809	608	634	946	648
	Total debt	217	202	126	403	397	877	1,506	1,499	1,506	2,143
	Net debt	12	(267)	(228)	(19)	29	136	1,143	1,163	910	2,000
	Shareholders’ equity	(32)	208	249	92	151	197	170	84	364	49
Returns, %
Returns, %	ROA	(46.48)	16.12	(16.73)	(14.36)	22.53	47.82	13.72	15.75	23.39	13.81
	ROIC	0.00	0.00	(208.92)	(57.81)	50.02	51.83	12.73	16.92	27.06	14.31
	ROE	(1,958.98)	71.60	(35.14)	(42.41)	106.33	231.44	110.23	222.07	198.42	153.59

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EXEL Exelixis, Inc.	$15.6B	18.8×	16.7×	+10.63% (above 0%: growing)	+25.00% (above 0%: growing)	+557.25% (above 0%: growing)	96.71%	39.51%	Compare
ASND Ascendis Pharma A/S	$14.9B	16.3×	13.0×	+119.88% (above 0%: growing)	n/m	+2,335.93% (above 0%: growing)	91.85%	64.98%	Compare
JAZZ Jazz Pharmaceuticals PLC	$13.9B	13.8×	17.3×	+15.55% (above 0%: growing)	n/m	+140.99% (above 0%: growing)	90.37%	20.54%	Compare
HALO Halozyme Therapeutics, Inc.	$13.8B	34.6×	10.6×	+47.67% (above 0%: growing)	+44.12% (above 0%: growing)	+141.18% (above 0%: growing)	83.54%	59.80%
BBIO BridgeBio Pharma, Inc.	$13.1B	— (loss-making)	— (loss-making)	+120.39% (above 0%: growing)	n/m	+16.59% (above 0%: growing)	93.83%	(43.94%)	Compare
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%	Compare
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
Median of peers	$12.7B	40.4×	17.0×	+17.73%	+21.21%	+4.88%	91.11%	18.33%

All 614 Biotechnology stocks →

Halozyme Therapeutics, Inc. (HALO) key facts

Strength: Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
Halozyme Therapeutics, Inc. (HALO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, HALO traded at $121.84, a market capitalization of $13.8 billion.
Return on equity was 153.6% and debt-to-equity 14.95.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.46 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.